Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

Creating strong employee engagement and retaining talent in the new normal

By Marie Little

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster receives CHMP recommendation

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

Novartis and BeiGene announce positive phase 3 trial results for hepatocellular carcinoma treatment

Hepatocellular carcinoma accounts for 75-85% of liver cancer diagnoses

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvements for lung cancer patients

Data showed a confirmed objective response rate of 53.8% in patients with HER2-mutant metastatic non-small cell lung cancer

regeneron headquarters

Regeneron’s fianlimab/Libtayo combination shows positive results in advanced melanoma treatment

The results were shared at the European Society for Medical Oncology Congress 2022

Pharmacogenomics

Pharmacogenomics supports and new era of precision medicine

Advances in medical science are always working towards the same goals; to improve quality of life, and clinical and economic outcomes for patients, caregivers, and health providers alike. But drug...

Page & Page Health

- PMLiVE

Building a brighter future with patient support programmes

By Danny Buckland

- PMLiVE

The benefits of patient support programmes in specific disease areas

By Charlotte Maule

- PMLiVE

AstraZeneca shares positive Tagrisso data in patients with EGFR-mutated lung cancer

Lung cancer is the leading cause of cancer death among both men and women

- PMLiVE

Amgen announces positive results for Lumakras colorectal cancer combination treatment

Results demonstrated a confirmed objective response rate of 30% and median progression free survival of 5.7 months

regeneron headquarters

Regeneron’s Libtayo shows promising results in phase 2 skin cancer trial

In the phase 2 trial, 50.6% of patients achieved the primary endpoint of complete pathologic response

- PMLiVE

OPEN Health appoints Stephen Chick as chief growth officer for Evidence & Access

Chick joins the consultancy from his role as vice president of business development at Symphony Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links